Proteon Therapeutics Announces Third Quarter 2018 Financial Results
November 07, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
August 29, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Second Quarter 2018 Financial Results
August 07, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
June 14, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces First Quarter 2018 Financial Results
May 09, 2018 08:10 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply
May 08, 2018 07:00 ET
|
Proteon Therapeutics, Inc.
Partners extend existing contract for manufacture of vonapanitase to 2029 as ongoing Phase 3 trial nears completionLonza Pharma & Biotech successfully scaled up a lab process at their Microbial...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
March 14, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
March 06, 2018 16:45 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
March 05, 2018 17:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th
November 08, 2017 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...